ImmunityBio, Inc. IBRX Segment Reporting — Loss on equity method investment

Similar metrics at other companies

QSROperating Segments — Income Loss From Equity Method Investments

$5.05M+593%

BBIOReportable Segment — Income (Loss) from Equity Method Investments

-$18.28M-17.5%

JLLReportable Subsegments — Income Loss From Equity Method Investments

$700K+16.7%

BBIOReportable Segment Aggregation Before Other Operating — Income Loss From Equity Method Investments

-$20.19M-155%

BWXTOperating Segments — Income Loss From Equity Method Investments

$7.59M+123%

CLXOperating Segments — Income Loss From Equity Method Investments

$4.75M+26.7%

Questions, answered.

What is ImmunityBio, Inc.'s segment reporting — loss on equity method investment?

ImmunityBio, Inc. (IBRX) reported segment reporting — loss on equity method investment of $0 in Q4 2025.

What is the long-term trend for ImmunityBio, Inc.'s segment reporting — loss on equity method investment?

Over 2 years (2023 to 2025), ImmunityBio, Inc.'s segment reporting — loss on equity method investment has grown at a -100.0% compound annual growth rate (CAGR), from -$7.55M to $0.

What does segment reporting — loss on equity method investment mean?

The company's portion of financial losses incurred by businesses it partially owns.

How do you interpret segment reporting — loss on equity method investment?

An increase in losses indicates poor performance of strategic partners or joint ventures, whereas a decrease or shift to profit signals successful collaboration.

How does segment reporting — loss on equity method investment compare across companies?

Standard in companies with complex partnership structures; often categorized under 'Equity in Losses of Unconsolidated Affiliates'.